Tatva Chintan Pharma Chem Limited has informed the Exchange regarding 'copy of the Report filed by the Promoter of the Company with SEBI under Regulation 10(7) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for shares acquired under Regulation 10(1)(a)(ii) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011'.
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Promoter Mr. Ajay Mansukhlal Patel acquired 7,15,345 equity shares (3.06%) of Tatva Chintan Pharma Chem through an inter-se transfer upon the dissolution and full partition of Ajay Mansukhlal Patel (HUF) on 06 February 2026. No monetary consideration was involved — this is a family arrangement for succession planning and rationalisation of family holdings. The aggregate promoter and promoter group shareholding remains unchanged at 72.02% before and after the transaction. Required fees of Rs. 1,77,000 (including 18% GST) have been paid to SEBI, and prior intimations under Regulation 10(5) on 29 January 2026 and disclosures under Regulation 10(6) on 09 February 2026 were already filed.
This is an internal promoter family restructuring with no change in total promoter shareholding and no cash transaction. There is no material impact on public shareholders or the stock price — purely a procedural compliance filing.